会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • SEARCH RESULT RELEVANCE BY DETERMINING QUERY INTENT
    • 通过确定查询内容搜索结果相关性
    • US20120150850A1
    • 2012-06-14
    • US12963186
    • 2010-12-08
    • SASI PARTHASARATHYMaksym RogovAndrey Zaytsev
    • SASI PARTHASARATHYMaksym RogovAndrey Zaytsev
    • G06F17/30
    • G06F16/9535
    • Embodiments of the present invention relate to systems, methods, and computer-storage media for determining search query intent based on search results retrieved in response to a search query. In one embodiment, a plurality of search results that are responsive to a search query are retrieved. The plurality of search results is ranked based on relevance to the search query. Additionally, an adult-content score is assigned to one or more of the plurality of search results based on categorizing an amount of adult content within each of the one or more plurality of search results. Further, a search-query-intent score is determined based on the adult-content score of each of the one or more plurality of search results and the ranking of each of the one or more plurality of search results.
    • 本发明的实施例涉及基于响应于搜索查询检索的搜索结果来确定搜索查询意图的系统,方法和计算机存储介质。 在一个实施例中,检索响应于搜索查询的多个搜索结果。 基于与搜索查询的相关性对多个搜索结果进行排名。 此外,基于对一个或多个多个搜索结果的每一个内的成人内容的数量进行分类,将成人内容得分分配给多个搜索结果中的一个或多个。 此外,基于一个或多个多个搜索结果中的每一个的成人内容分数和一个或多个多个搜索结果中的每一个的排名来确定搜索查询意图分数。
    • 5. 发明申请
    • PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS
    • 吡咯嗪,三氮唑及其作为药物代用品
    • US20110092490A1
    • 2011-04-21
    • US12934798
    • 2009-03-26
    • Shudong WangShenhua ShiAndrey ZaytsevPeter Martin Fischer
    • Shudong WangShenhua ShiAndrey ZaytsevPeter Martin Fischer
    • A61K31/5377C07D417/14C07D417/04A61K31/506A61K31/496A61K31/551A61P35/00A61P35/02A61P17/06A61P9/00A61P3/00A61P37/00A61P31/00
    • C07D417/04C07D251/18
    • A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X1 and X2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N, Se; Z is NH, NHCO, NHSO2, N-alkyl, CH2NH, CH2N-alkyl, CH2, CH2CH2, CH═CH, CH2CONH, SO2, or SO; Y is N CR3; R1, R2, R5, R6, R7, R8 and R9 are each independently H, or a substituent; R3, when present, is selected from alkyl and a substituent, with the proviso that when Y is CR3, Ar is a 5-membered heterocycle comprising one or two N heteroatoms and Z is NH, then R3 is selected from C3+ alkyl and a substituent; R4 is selected from H, alkyl and R13 as hereinbefore defined, with the proviso that when R3 is absent, R4 is selected from alkyl and a substituent; processes for the preparation thereof, intermediates and precursors therefore and the use thereof as a medicament, and therapeutic compositions comprising the compound.
    • 式(I)化合物及其药学上可接受的盐或溶剂化物和生理上可水解,增溶或可固化的衍生物,其中:Ar是5元杂芳基环,其中X 1和X 2是一个或两个杂原子或Ar是6-元芳环 其中杂原子选自S,O,N,Se; Z是NH,NHCO,NHSO 2,N-烷基,CH 2 NH,CH 2 N-烷基,CH 2,CH 2 CH 2,CH = CH,CH 2 CONH,SO 2或SO; Y是N CR3; R1,R2,R5,R6,R7,R8和R9各自独立地为H或取代基; 当存在时,R3选自烷基和取代基,条件是当Y为CR 3时,Ar为包含一个或两个N个杂原子且Z为NH的5元杂环,则R3选自C3 +烷基和取代基 ; R 4选自如上文所定义的H,烷基和R 13,条件是当R 3不存在时,R 4选自烷基和取代基; 因此,其制备方法,中间体和前体及其作为药物的用途,以及包含该化合物的治疗组合物。